罗沙司他对维持性血液透析肾性贫血患者的影响

Effects of Roxadustat on Patients with Renal Anemia after Maintenance Hemodialysis

目的:探讨罗沙司他对维持性血液透析(MHD)肾性贫血患者的影响。方法:选取2021年1月—2023年9月在萍乡市人民医院肾内科治疗80例MHD肾性贫血患者,按照1∶1随机数字表法将其分为观察组(n=40)和对照组(n=40)。观察组予以罗沙司他治疗,对照组予以人促红素治疗,均持续治疗6个月。比较两组临床效果、血常规指标[血红蛋白(Hb)、红细胞计数(RBC)、红细胞压积(HCT)]、铁代谢指标[血清铁(Fe)、总铁结合力(TIBC)、转铁蛋白饱和度(TSAT)]、血前白蛋白(PAB)、白蛋白(Alb)及炎症指标[C反应蛋白(CRP)]水平。记录两组治疗期间不良反应情况。结果:观察组临床治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组Hb、RBC、HCT均高于对照组,差异均有统计学意义(P<0.05);观察组Fe、TIBC、TSAT水平均高于对照组,差异均有统计学意义(P<0.05);两组血PAB、Alb水平比较,差异均无统计学意义(P>0.05);观察组炎症指标(CRP)水平低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率(10.00%)与对照组(15.00%)比较,差异无统计学意义(P>0.05)。结论:罗沙司他与人促红素均对MHD肾性贫血患者均具有一定的临床治疗效果,但罗沙司他纠正MHD肾性贫血的效果更为明显,可有效改善患者机体代谢功能,减轻炎症反应,且安全性较好。

Objective:To explore the effects of Roxadustat on patients with renal anemia after maintenance hemodialysis (MHD).Method:A total of 80 patients with renal anemia undergoing MHD in Nephrology Department of Pingxiang People's Hospital were enrolled from January 2021 to September 2023,they were divided into observation group (n=40) and control group (n=40) by 1∶1 random number table method.The observation group was treated with Roxadustat,while the control group was treated with Human Erythropoietin,both were lasted for 6 months.The clinical effect,blood routine indicators[hemoglobin (Hb),red blood cell count (RBC),hematocrit (HCT)],iron metabolism indexes[serum iron (Fe),total iron binding capacity (TIBC),transferrin saturation (TSAT)],serum prealbumin (PAB),albumin (Alb) and inflammation indicators[C reactive protein (CRP)]in the two groups was compared.The adverse reactions in the two groups during treatment were recorded.Result:The total effective rate of clinical treatment in observation group was higher than that in control group,the difference was statistically significant (P<0.05).After treatment,Hb,RBC and HCT in observation group were higher than those in control group,the differences were statistically significant (P<0.05);levels of Fe,TIBC and TSAT were higher than those in control group,the differences were statistically significant (P<0.05);there were no significant differences in serum PAB and Alb between the two groups (P>0.05);CRP level in observation group was lower than that in control group,the difference was statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between observation group (10.00%) and control group (15.00%) (P>0.05).Conclusion:Both Roxadustat and Human Erythropoietin have certain clinical effect in MHD patients with renal anemia.However,Roxadustat has more obvious correction effect on renal anemia after MHD,which can effectively improve metabolic function and relieve inflammatory response,with good safety.